- Home
- IMAB vs CEE Comparison
IMAB vs CEE Comparison
Compare IMAB & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- CEE
- Stock Information
- Founded
- IMAB 2014
- CEE 1990
- Country
- IMAB United States
- CEE Germany
- Employees
- IMAB N/A
- CEE N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- CEE Finance Companies
- Sector
- IMAB Health Care
- CEE Finance
- Exchange
- IMAB Nasdaq
- CEE Nasdaq
- Market Cap
- IMAB 83.8M
- CEE 68.6M
- IPO Year
- IMAB 2020
- CEE N/A
- Fundamental
- Price
- IMAB $1.06
- CEE $12.27
- Analyst Decision
- IMAB Strong Buy
- CEE
- Analyst Count
- IMAB 3
- CEE 0
- Target Price
- IMAB $8.00
- CEE N/A
- AVG Volume (30 Days)
- IMAB 410.6K
- CEE 22.0K
- Earning Date
- IMAB 08-28-2024
- CEE 01-01-0001
- Dividend Yield
- IMAB N/A
- CEE 3.86%
- EPS Growth
- IMAB N/A
- CEE N/A
- EPS
- IMAB N/A
- CEE N/A
- Revenue
- IMAB $3,492,091.00
- CEE N/A
- Revenue This Year
- IMAB N/A
- CEE N/A
- Revenue Next Year
- IMAB N/A
- CEE N/A
- P/E Ratio
- IMAB N/A
- CEE N/A
- Revenue Growth
- IMAB N/A
- CEE N/A
- 52 Week Low
- IMAB $0.99
- CEE $7.80
- 52 Week High
- IMAB $2.54
- CEE $10.32
- Technical
- Relative Strength Index (RSI)
- IMAB 40.43
- CEE 75.08
- Support Level
- IMAB $1.02
- CEE $10.60
- Resistance Level
- IMAB $1.12
- CEE $13.36
- Average True Range (ATR)
- IMAB 0.08
- CEE 0.41
- MACD
- IMAB -0.01
- CEE 0.24
- Stochastic Oscillator
- IMAB 20.00
- CEE 74.09
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.